MECHANISM OF ACTION

MECHANISM OF ACTION

RYSTIGGO is the first and only
FDA-approved FcRn blocker for the
treatment of gMG in adult patients
who are
anti-AChR or anti-MuSK Ab+1,2*

gMG

gMG is a chronic, unpredictable,

heterogenous, autoimmune disease3

Up to 95% of gMG patients

present with either AChR or MuSK autoantibodies4

*The precise mechanism through which RYSTIGGO exerts therapeutic effects in gMG is unknown.

gMG is a chronic, unpredictable,

heterogenous, autoimmune disease3

Up to 95% of gMG patients

present with either AChR or MuSK autoantibodies4

*The precise mechanism through which RYSTIGGO exerts therapeutic effects in gMG is unknown.

RYSTIGGO is engineered to block FcRn1

RYSTIGGO specifically targets and blocks IgG antibodies from binding to FcRn.1,2

is an FcRn blocker indicated for the treatment of gMG in adult patients who are anti-AChR or anti-MuSK antibody positive1

High-Affinity Binding

RYSTIGGO binds to FcRn with high affinity, reducing IgG recycling and leading to degradation.5†

Clinical data with RYSTIGGO have not identified any clinically relevant impact on levels of albumin, which binds at a different site on FcRn.5,6

Learn more about the pharmacodynamic effects of RYSTIGGO

VIEW IgG DATA

is an FcRn blocker indicated for the treatment of gMG in adult patients who are anti-AChR or anti-MuSK antibody positive1

Discover how RYSTIGGO works

Learn more about how blocking FcRn removes AChR and MuSK autoantibodies.1

Based on in-vitro data.5
Ab+=antibody positive; AChR=acetylcholine receptor; FcRn=neonatal Fc receptor; gMG=generalized myasthenia gravis; IgG=immunoglobulin G; MuSK=muscle-specific tyrosine kinase.

References:

  1. RYSTIGGO [Prescribing Information]. Smyrna, GA: UCB, Inc.
  2. Lledo-Garcia R, Dixon K, Shock A, Oliver R. Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: translation from preclinical stages to the clinic. CPT Pharmacometrics Syst Pharmacol. 2022;11(1):116-128. doi:10.1002/psp4.12739
  3. Trouth AJ, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. Autoimmune Dis. 2012;2012:1-10. doi:10.1155/2012/874680
  4. Gambino CM, Agnello L, Ciaccio AM, et al. Detection of antibodies against the acetylcholine receptor in patients with myasthenia gravis: a comparison of two enzyme immunoassays and a fixed cell-based assay. J Clin Med. 2023;12(14):1-10. doi:10.3390/jcm12144781
  5. Smith B, Kiessling A, Lledo-Garcia R, et al. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs. 2018;10(7):1111-1130. doi:10.1080/19420862.2018.1505464
  6. Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22(5):383-394. doi:10.1016/S1474-4422(23)00077-7
  7. Gable K, Guptill J. Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis. Front Immunol. 2020;10(3052):1-9. doi:10.3389/fimmu.2019.03052
  8. Wolfe GI, Ward ES, de Haard H, et al. IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis. J Neurol Sci. 2021;430:1-10. doi:10.1016/j.jns.2021.118074
  9. Mané-Damas M, Molenaar PC, Ulrichts P, et al. Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders. Autoimmune Rev. 2022;21(7):1-10. doi:10.1016/j.autrev.2022.103104
  10. Rodolico C, Bonanno C, Toscano A, et al. MuSK-associated myasthenia gravis: clinical features and management. Front Neurol. 2020;11(660):1-5. doi:10.3389/fneur.2020.00660